论文部分内容阅读
目的:分析血清白细胞介素-6(IL-6)、微小RNA-17-5p(miR-17-5p)水平与卵巢癌患者化疗后生存期的相关性。方法:选取行手术治疗联合术后化疗的65例卵巢癌患者作为病例组,选取50名健康体检者作为对照组,选取50例良性卵巢疾病患者作为良性疾病组,对病例组患者术前及术后14d的血清IL-6、miR-17-5p水平进行检测和比较,对良性疾病组和对照组研究对象的血清IL-6、miR-17-5p水平进行检测和比较,对病例组患者进行随访,对其总生存期(OS)和无疾病进展生存期(PFS)进行观察和比较。结果:病例组患者血清IL-6、miR-17-5p表达水平显著高于良性疾病组,良性疾病组患者的血清IL-6、miR-17-5p表达水平显著高于对照组,各组之间的差异均有统计学意义(P<0.05)。病例组患者术后14d血清IL-6、miR-17-5p表达水平较手术前显著下降,差异均有统计学意义(P<0.05)。血清IL-6、miR-17-5p高表达的卵巢癌患者中TNM分期为Ⅲ~Ⅳ期的比例较高,差异均有统计学意义(P<0.05)。血清IL-6、miR-17-5p高表达卵巢癌患者的OS和PFS明显短于血清IL-6、miR-17-5p低表达患者,差异均有统计学意义(P<0.05)。血清IL-6和miR-17-5p同时呈现低表达的卵巢癌患者的OS和PFS水平最高,血清IL-6或miR-17-5p其中之一呈现高表达卵巢癌患者的OS和PFS水平居中,而血清IL-6和miR-17-5p同时呈现高表达的OS和PFS水平最低,差异均有统计学意义(P<0.05)。结论:卵巢癌患者可表现为血清IL-6、miR-17-5p水平的显著升高,在手术治疗后,其水平会出现下降,术前较高的血清IL-6、miR-17-5p表达水平与较短的生存期和不良预后具有关联性,可作为预测患者预后的辅助指标。
Objective: To analyze the correlation between the levels of serum interleukin-6 (IL-6), microRNA-17-5p (miR-17-5p) and the survival of patients with ovarian cancer after chemotherapy. Methods: A total of 65 patients with ovarian cancer who underwent combined surgery and postoperative chemotherapy were enrolled in this study. Fifty healthy subjects were selected as the control group. Fifty patients with benign ovarian diseases were selected as benign disease group. Serum levels of IL-6 and miR-17-5p were detected and compared 14 days later. Serum levels of IL-6 and miR-17-5p in benign disease group and control group were detected and compared, and patients in the case group Follow-up, their overall survival (OS) and disease-free survival (PFS) were observed and compared. Results: Serum levels of IL-6 and miR-17-5p were significantly higher in case group than in benign group. The levels of IL-6 and miR-17-5p in benign disease group were significantly higher than those in control group The differences between the two groups were statistically significant (P <0.05). The serum level of IL-6 and miR-17-5p in patients after operation at 14th day were significantly lower than those before operation (P <0.05). Serum IL-6, miR-17-5p overexpression in ovarian cancer patients TNM staging for the high proportion of stage Ⅲ ~ Ⅳ, the difference was statistically significant (P <0.05). Serum IL-6, miR-17-5p overexpression in ovarian cancer patients with OS and PFS was significantly shorter than serum IL-6, miR-17-5p low expression of patients, the difference was statistically significant (P <0.05). The serum levels of OS and PFS in patients with ovarian cancer with low expression of both IL-6 and miR-17-5p were the highest. Serum IL-6 or miR-17-5p showed high OS and PFS levels in patients with high expression of ovarian cancer , While the levels of OS and PFS with high expression of IL-6 and miR-17-5p in serum at the same time were the lowest, with statistical significance (P <0.05). Conclusions: Serum levels of IL-6 and miR-17-5p may be significantly elevated in patients with ovarian cancer. After surgery, the levels of IL-6 and miR-17-5p may be decreased. Serum levels of IL-6 and miR-17-5p The expression level is associated with shorter survival time and poor prognosis, and can be used as a supplementary indicator to predict the prognosis of patients.